Search

Copyright of Argos (1699-7875) is the property of Grupo Asis Biomedia, S.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The article focuses on the medical and surgical management of canine osteoarthritis, a common joint disease that significantly impacts a dog's quality of life. The article discusses the disease's prevalence, the consequences of pain associated with osteoarthritis, its diagnosis, prognosis, and the essential pillars of its management, including pharmaceutical and surgical approaches, illustrated through a case study involving a German Shepherd with severe hip dysplasia.

The article offers several veterinary medicine news brief as of October 2022. Topics discussed include Veterinary Online Open Course will address osteoarthritis and highlighting the importance of early diagnosis and role of physical therapy and rehabilitation; Ceva Salud Animal accompanied the veterinarians during the seventh edition of the European Dirofilaria and Angiostrongylus Days, held on September 23-24, 2022 and Ceva Salud Animal accompanied the veterinarians.

The article provides information on the diagnosis of osteoarthrosis in dogs affecting the hip joints, elbow and knee including destruction of articular cartilage with hypertrophy, analgesic treatment with antiinflammatories nonsteroidal drugs and somatosensory component in veterinary medicine for pathogenesis of osteoarthritis.

The article offers veterinary industry news brief as of September 2022. Topics discussed include Complutense Conference of the Equine Clinic organized by the Complutense University with the collaboration of Zoetis; Elanco Animal Health has developed a new initiative to promote the management of canine osteoarthritis from early stages and provide quality of life to those dogs suffering from this pathology and veterinary companion under the Aggregata denomination Comprehensive Feline Medicine.

The article reports on Zoetis' presence at Iberzoo+Propet 2023 and Vetmadrid 2023, which showcased its innovative products such as VetScan Imagyst for diagnosis using artificial intelligence, and its monoclonal antibodies for treating osteoarthritis and dermatitis in dogs and cats.

The article focuses on the Artrochallenge contest by Zoetis, aimed at promoting scientific veterinary knowledge around osteoarthritis in cats and dogs through challenges and clinical cases.

The article reports that Zoetis has launched the Joint Health One Health campaign to facilitate communication and awareness among veterinarians and customers about the impact of osteoarthritis (OA) on pets' health and well-being, and to make pet owners aware of high prevalence of OA,.

The article reports that Zoetis supports veterinarian-owner communication regarding osteoarthritis (OA), a common problem affecting pets, by promoting awareness campaigns and providing resources for early detection and treatment. Topics include pet owners confuse OA symptoms with general aging or other health problems, leading to missed opportunities for treatment; and Zoetis provides veterinarians with materials to educate owners and increase visits to the vet to help manage OA pain in pets.

The article reports that Elanco Animal Health launches second edition of the OA Clinical Case Contest to promote early intervention for osteoarthritis in dogs, and veterinarians can submit osteoarthritis cases or mobility disorders in dogs, with registration for the VMX 2024 Congress in Orlando.

The article reports that Zoetis launches "OA-on the road Challenge" playful-didactic workshops on osteoarthritis treatment for pets that will take place in various cities until April, and challenge focuses on disease impact, treatment with monoclonal antibodies, and the use of nutraceuticals.

An interview with Sergio Pedrosa, Veterinary Technical Manager of Dômes Pharma for Iberia, is presented. Topics include DogStemis a pioneering product in advanced cell therapy registered in the European Union and the United Kingdom for the treatment of dogs with osteoarthritis (OA); and the DogStem reduces pain and lameness, improves mobility and quality of life for dogs after a single intra-articular injection additional surgery under anesthesia, and a standardized product of veterinary.

The article informs about Multimodal treatment of canine and feline osteoarthritis with addition to conventional analgesics, there are new products for the control of chronic pain in patients. Topics include joint use of drugs and non-pharmacological therapies is key in the management of the disease; and diagnosis Osteoarthrosis (OA)is defined as the end result of a slowly evolving disease or group of diseases that affects mobile joints and is characterized by causing the gradual onset of pain.

The article informs that Elanco has launched various initiatives to spread knowledge about canine osteoarthritis with the aim of contributing to the early diagnosis of this disease, which is key to its management. It mentions launch premieres for "Oh, my OA" in Barcelona and Madrid to develop the awareness of canine osteoarthritis among dogs, and debates in which the important aspects of the disease were addressed.

The article focuses on clinical management of pathologies joint in dogs and osteoarticularproblems in dogs. It mentions therapeutic management of this type of pathologies in the clinic that limit the quality of life of patients and joint produces an imbalance between biosynthesis and degradation of cartilaginous matrix. It also mentions presence of osteophytes and enthesophytes and leads to fibrosis of the synovial membrane.

The article focuses on natural treatments in traumatology and neurology as benefits can contribute to the dog and the cat. It mentions AlgiGreen, from Dr. Green by Drasanvi, is the first nutritional supplement in the Palmitoylethanolamide (PEA)-based market for cases of inflammation and joint pain. It also mentions recommended options against pathologies of the musculoskeletal system, such as osteoarthritis, arthritis and other ailments musculoskeletal systems.

The article reports that Nuzoa has announced the signing of an agreement exclusive distribution in Spain products from TheraVet, a pioneer company in the treatment of osteoarticular diseases in pets.

The article reports that French group Dômes has announced the signing of an exclusive association with the Spanish company of EquiCord biotechnology to distribute the first cell-based drug expected mother for the treatment of canine osteoarthritis.

An interview with Pedro Miguel Sousa Castro, Head of the Anesthesia Service and Analgesia of the Molins Veterinary Hospital, is presented. Topics discussed include osteoarthritis in the canine species; predisposing factors for disease, and racial predisposition (genetic influence) is one of the most important and multimodal treatment for patients who have obesity loss has to be the primary objective.

The article interviews Raquel Mesquita, product manager at Companion Animals. Topics include data related to the prevalence of canine osteoarthritis (CO), a degenerative disease; her views on the benefits of the Veterinary HPM Joint & Mobility diet from her company which is designed to aid the metabolism of joints in cases of CO and for the control of body weight; and the benefits of the eggshell membrane included in the diet.

The article talks about the presentation of Ecuphar's NSAID, Daxocox, that brought together veterinarians from different disciplines to treat existing need to address the management of osteoarthritis. Topics discussed include Daxocox indicating for pain relief and inflammation in canine patients with OA (degenerative joint disease); diagnostic and therapeutic by general veterinarians; and success of obesity management in patients with osteoarthritis.

An interview with veterinarian Josep Maria Riera Aguado, is presented. Topics discussed include compliance with the prescribed treatment by the pet owner and breakthrough pain; controlling the pain and inflammation in canine osteoarthritis (OA); evaluation and treatment of pain in dogs and cats; and short-lived pain bursting into the analgesia controllng pain.

The article reports that Librela and Solensia are a new pharmacological group indicated for pain due to osteoarthritis in dogs and cats. It mentions that they are administered as a monthly subcutaneous injection to relieve pain, meanwhile pet owners observed a reduction in pain, which translated into increased physical activity, sociability, and quality of life.

An interview with Carmen Alamán, Pet Marketing Manager at Zoetis Spain, is presented. Topics discussed include considering Librela, bedinvetmab, as the first antibody monoclonal administered monthly approved in the European Union for relieve pain associated with osteoarthritis in dogs; veterinarians having a new treatment option for osteoarthritis; and single injection of Librela.

The article offers information on several news briefs related to animal health, Veterinary and drug industry. Topics include Distrivet, national benchmark in the distribution of animal health products expanded and improved its warehouse equipped with the most innovative logistics technologies; Dr. Duncan Lascelles, President of the WSAVA Global Pain Council (GPC) explored mechanisms related to pain and inflammation in dog and cat osteoarthritis; and awareness of vaccinating against rabies.

An interview with José Luis Aguirregomezcorta, head of veterinary medicine manufacturer Laboratorios Karizoo SA is presented. He discussed various topics including treatment of osteoarthritis in animals, its progression, degenerative development of osteoarthritis, its inflammation and osteoarthritis in dogs.

An interview with drug developer André Amanda is presented. He discussed various topics including development of the drug Galliprant by him, how it will be used for treating osteoarthritis in dogs, its risk factors, disease prevalence, researches on dog diseases and consequences of delayed treatment.

The article reports on EP4 receiver for the canine osteoarthritis treatment. Topics discussed include side effects associated with the management of Chronic osteoarthritis (OA) through NSAIDs; piprants drug which acts as an antagonists of Prostaglandin receptor (ARP); and fuction of four subtypes of receptors coupled to G proteins, called EP receivers: EP1, EP2, EP3 and EP4.

The article reports that Zoetis Inc. has developed Trocoxil, a non-steroidal anti-inflammatory drug, for canine osteoarthritis.

The article reports on the importance of nutrition in canine osteoarthritis. Topics discussed include the role of nutrition in the management of osteoarthritis; how it help in weight control and contribute as specific beneficial nutrient for joints; and a graph showing a group of dogs that receive a food which includes the curcumin complex, hydrolyzed collagen and polyphenols of green tea.